The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Engineered nanomedicine for myeloma and bone microenvironment targeting
Open accessAbstract
Significance: Limited treatment options exist for cancer within the bone, as demonstrated by the inevitable, pernicious course of metastatic breast, prostate, and blood cancers. The difficulty of eliminating bone-residing cancer necessitates novel, alternative treatments to manipulate the tumor cells and their microenvironment, with minimal off-target effects. To this end, we engineered bone-homing, stealth nanoparticles to deliver anticancer, bone-stimulatory drugs, and demonstrated their utility with bortezomib (a model drug) and multiple myeloma (a model cancer). To test our hypothesis that increasing bone volume and strength inhibits tumor growth, mice were treated with these nanoparticles before being injected with cancer cells. Results demonstrated significantly slower myeloma growth and prolonged survival. Our research demonstrates the potential of bone-homing nanomedicine as an efficacious cancer treatment mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ravindran, J., Nair, H. B. B., Sung, B., Prasad, S., TEKMAL, R. R., & Aggarwal, B. B. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.023 · Cited by 138
RetractedDempster, D. W., Compston, J. E., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., Recker, R. R., & Parfitt, A. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1805 · Cited by 2,543
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Self-citationHrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Self-citationInteractions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Self-citationAzab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186668 · Cited by 428
Self-citationTransepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery
Pridgen, E. M., Alexis, F., Kuo, T. T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R. S., Langer, R., & Farokhzad, O. C. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007049 · Cited by 405
Self-citationPathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
Garrett, I. R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S. E., Gallwitz, W., Kim, K. B., Hu, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16198 · Cited by 328
Pathogenesis of myeloma bone disease
Roodman, G. D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22403 · Cited by 296
Giuliani, N., Morandi, F., Tagliaferri, S., Lazzaretti, M., Bonomini, S., Crugnola, M., Mancini, C., Martella, E., Ferrari, L., Tabilio, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-059188 · Cited by 267
‘Magic bullets’ for bone diseases: progress in rational design of bone-seeking medicinal agents
Zhang, S., Gangal, G., & Uludağ, H. (2007) · Chem. Soc. Rev. · doi:10.1039/b512310k · Cited by 237
Self-citationResponse to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Zangari, M., Esseltine, D., Lee, C., Barlogie, B., Elice, F., Burns, M. J., Kang, S., Yaccoby, S., Najarian, K., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05733.x · Cited by 199
Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Gorgun, G., Patel, K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0763 · Cited by 167
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment
Heider, U., Kaiser, M., Müller, C., Jakob, C., Zavrski, I., Schulz, C., Fleissner, C., Hecht, M., & Sezer, O. (2006) · European Journal of Haematology · doi:10.1111/j.1600-0609.2006.00692.x · Cited by 161
Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
Reagan, M. R., & Ghobrial, I. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2212 · Cited by 152
Self-citationThe Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Leleu, X. P., Jia, X., Runnels, J. M., Ngo, H. T., Moreau, A., Farag, M., Spencer, J. A., Pitsillides, C. M., Hatjiharissi, E., Roccaro, A. M., et al. (2007) · Blood · doi:10.1182/blood-2007-05-092098 · Cited by 144
Self-citationNanoparticles for Targeted and Temporally Controlled Drug Delivery
Swami, A., Shi, J., Gadde, S., Votruba, A. R., Kolishetti, N., & Farokhzad, O. C. (2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8_2 · Cited by 108
Self-citationMultifunctional Nanoparticles for Drug Delivery Applications
(2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8 · Cited by 81
Maillard, S., Ameller, T., Vergnaud, J., Gougèlet, A., Gouilleux, F., Legrand, P., Marsaud, V., Fattal, E., Sola, B., & Renoir, J. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.023 · Cited by 60
Ozaki, S., Tanaka, O., Fujii, S., Shigekiyo, Y., Miki, H., Choraku, M., Kagawa, K., Asano, J., Takeuchi, K., Kitazoe, K.-I., et al. (2007) · International Journal of Hematology · doi:10.1532/ijh97.07030 · Cited by 56
Sayed, D. M., Al-Sadoon, M. K., & Badr, G. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/386286 · Cited by 34
Dou, J., Yang, C., Wang, J., et al. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s38447 · Cited by 25
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Self-citationCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Targeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Self-citationControl of polymeric nanoparticle size to improve therapeutic delivery
Hickey, J. W., Santos, J. L., Williford, J.-M., & Mao, H.-Q. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.006 · Cited by 379
Hu, Q., Sun, W., Wang, J., Ruan, H., Zhang, X., Ye, Y., Shen, S., Wang, C., Lu, W., Cheng, K., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0310-2 · Cited by 310
Metadata
- Authors
- Swami, A., Reagan, M. R., Basto, P., Mishima, Y., Kamaly, N., Glavey, S., Zhang, S., Moschetta, M., Seevaratnam, D., Zhang, Y., Liu, J., Memarzadeh, M., Wu, J., Manier, S., Shi, J., Bertrand, N., Lu, Z. N., Nagano, K., Baron, R., Sacco, A., Roccaro, A. M., Farokhzad, O. C., & Ghobrial, I. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-06-30
- Volume
- 111
- Issue
- 28
- Pages
- 10287-10292
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2089220360
- Cited by
- 283
- References
- 24
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.